Albert Garcia-Romeu

2 months ago | gpsych.bmj.com | Jérémie Richard |Albert Garcia-Romeu |Jack E Henningfield

The United States Food and Drug Administration’s (FDA’s) August 2024 determination that an additional phase III study will be required to consider the approval of midomafetamine for the treatment of post-traumatic stress disorder (PTSD) could delay the potential approval of this promising treatment by several years.1 In principle, the FDA’s expanded access pathway could enable broader access to investigational treatments as clinical trials continue.

Mar 25, 2024 | journals.plos.org | Orrin D. Ware |Albert Garcia-Romeu |Johns Hopkins |C. Austin Zamarripa

Loading metrics Open Access Peer-reviewedResearch Article Citation: Ware OD, Garcia-Romeu A, Zamarripa CA, Hughes T, Wager L, Spindle T (2024) Codeine and promethazine: Exploratory study on “lean” or “sizzurp” using national survey data and an online forum. PLoS ONE 19(3): e0301024.

Mar 12, 2024 | liebertpub.com | Justin C. Strickland |Albert Garcia-Romeu |Matthew Johnson

*Address correspondence to: Matthew W. Johnson, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224-6823, USA, E-mail Address: [email protected] of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Dec 18, 2023 | acsjournals.onlinelibrary.wiley.com | Johannes Thrul |Zofia Kozak |Michael A. Carducci |Albert Garcia-Romeu

Corresponding Author Johannes Thrul PhD Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA Centre for Alcohol Policy Research, La Trobe University, Melbourne, Victoria, Australia Correspondence Johannes Thrul, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 887, Baltimore, MD 21205, USA.

Oct 9, 2023 | onlinelibrary.wiley.com | Oliver Grundmann |Albert Garcia-Romeu |Christopher R. McCurdy |Abhisheak Sharma

Corresponding Author Oliver Grundmann Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA Correspondence Oliver Grundmann, Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Drive, Room P3-20, Gainesville, FL 32611, USA. Email: [email protected] Contribution: Conceptualization (lead), Supervision (lead), Writing - original draft (lead), Writing - review & editing (equal)Search for more papers by this author